Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
about
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.Pharmacodynamic modelling of biomarker data in oncology.Sense and sensibility: the use of cell death biomarker assays in high-throughput anticancer drug screening and monitoring treatment responses.A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.Biomarker method validation in anticancer drug developmentImmunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinomaClinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.Inhibitor of apoptosis proteins as targets for anticancer therapy.IAPs: what's in a name?Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapyIAP-targeted therapies for cancer.Biomarkers of apoptosis.Mechanism-based bioanalysis and biomarkers for hepatic chemical stress.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Apoptosis: a clinically useful measure of antiretroviral drug toxicity?Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.Serum efficacy biomarkers for oncology.Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases.Circulating biomarkers in hepatocellular carcinomaA Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis PatientsPlasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer
P2860
Q33393931-90235A37-7D76-4643-A064-2D17D54BDB96Q33400716-614506BD-070F-4CBD-8C1C-3258ECF6B80EQ33847836-90379C29-994A-4F4B-9D11-058BF15CE230Q34241935-388CC482-D77C-4E11-8E4E-C54F6F10F712Q34626314-B6CDA0A8-161B-4647-959D-A89B228FD0D3Q35021208-63A754E3-C956-4E19-9003-2D9D0E347113Q35998447-A2F0CA6F-CB86-4054-AC8C-497F55A9E2B9Q36385291-50412971-A057-455D-A98E-078CFB66B0C1Q36484621-F29208B0-BC9D-46AF-AA45-8148DDB9FEFCQ36661995-9E5658FC-E300-4B17-B1F1-6B40F938BEE0Q36897795-4A520F0D-0A8D-413F-92BC-A141A62B7A7BQ36950485-BD85D14F-2518-4D76-B127-19C640407E53Q37148694-05CCE4FB-CD39-4D39-A14A-052A608F0E67Q37278502-4B76066D-98F4-4278-B424-E11878C76755Q37302745-F74296D2-823B-43EB-AFB1-97AA783FDD0FQ37400048-C192F9B0-FBB3-4C44-830C-1F62CD061DECQ37557613-78D6ED5A-501E-4551-A7F3-07457BAAC2A5Q37602717-64CFBEB0-71EF-4CEE-8AC5-E9FC25E2F8C6Q37604387-3DB0BCDA-F504-4FCF-9C68-69645CBAE761Q37705010-A07B5B8A-D064-4C66-BAE2-4DBC47306E2DQ37755150-6E518E63-59AA-40C7-B62E-A8E6807F4DD6Q39886859-7BA561AD-771C-4EA1-9CD7-DD39ED49B212Q43421009-36BF0F10-0AD6-449A-8F7C-630015831E84Q50652032-A7DCA7B3-191B-4967-B612-4B15F840E573Q58282111-C47C4DAE-1C4A-457A-AE9E-726F9B5EB217Q58282319-94E4484B-5ECA-424B-A576-34F94718881FQ58599860-5C1FF503-EFF5-4ADD-8448-E3C1FD5BAABE
P2860
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@ast
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@en
type
label
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@ast
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@en
prefLabel
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@ast
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@en
P2093
P2860
P356
P1476
Method validation and prelimin ...... tor of apoptosis protein XIAP.
@en
P2093
J Cummings
J R Ganganagari
P2860
P2888
P356
10.1038/SJ.BJC.6603220
P407
P577
2006-07-01T00:00:00Z